DK3277815T3 - Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser - Google Patents
Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser Download PDFInfo
- Publication number
- DK3277815T3 DK3277815T3 DK16716413.6T DK16716413T DK3277815T3 DK 3277815 T3 DK3277815 T3 DK 3277815T3 DK 16716413 T DK16716413 T DK 16716413T DK 3277815 T3 DK3277815 T3 DK 3277815T3
- Authority
- DK
- Denmark
- Prior art keywords
- clampsy
- treatment
- angiogenic disorders
- oligonucleotide compounds
- oligonucleotide
- Prior art date
Links
- 108091034117 Oligonucleotide Proteins 0.000 title 1
- 230000002491 angiogenic effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562142745P | 2015-04-03 | 2015-04-03 | |
| US201662291678P | 2016-02-05 | 2016-02-05 | |
| US201662291961P | 2016-02-05 | 2016-02-05 | |
| PCT/US2016/025731 WO2016161378A1 (en) | 2015-04-03 | 2016-04-01 | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3277815T3 true DK3277815T3 (da) | 2021-12-13 |
Family
ID=55752786
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16716413.6T DK3277815T3 (da) | 2015-04-03 | 2016-04-01 | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US9862952B2 (da) |
| EP (2) | EP3277815B1 (da) |
| CA (1) | CA2980339A1 (da) |
| DK (1) | DK3277815T3 (da) |
| ES (1) | ES2901455T3 (da) |
| HU (1) | HUE057431T2 (da) |
| PL (1) | PL3277815T3 (da) |
| PT (1) | PT3277815T (da) |
| RS (1) | RS62672B1 (da) |
| SI (1) | SI3277815T1 (da) |
| WO (1) | WO2016161378A1 (da) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5697993B2 (ja) | 2008-02-11 | 2015-04-08 | アールエックスアイ ファーマシューティカルズ コーポレーション | 修飾ＲＮＡｉポリヌクレオチドおよびその使用 |
| CA2743981C (en) | 2008-09-22 | 2019-01-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| US9074211B2 (en) | 2008-11-19 | 2015-07-07 | Rxi Pharmaceuticals Corporation | Inhibition of MAP4K4 through RNAI |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| CN103108642B (zh) | 2010-03-24 | 2015-09-23 | 雷克西制药公司 | 皮肤与纤维化症候中的rna干扰 |
| EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING |
| CA2794187C (en) | 2010-03-24 | 2020-07-14 | Rxi Pharmaceuticals Corporation | Rna interference in ocular indications |
| EP3079707A4 (en) | 2013-12-02 | 2017-10-18 | RXi Pharmaceuticals Corporation | Immunotherapy of cancer |
| EP3137119B1 (en) | 2014-04-28 | 2020-07-01 | Phio Pharmaceuticals Corp. | Methods for treating cancer using a nucleic acid targeting mdm2 |
| JP6836987B2 (ja) | 2014-09-05 | 2021-03-03 | フィオ ファーマシューティカルズ コーポレーションＰｈｉｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏｒｐ． | Ｔｙｒまたはｍｍｐ１を標的とする核酸を用いて老化および皮膚障害を処置するための方法 |
| WO2016161388A1 (en) | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| EP3277815B1 (en) | 2015-04-03 | 2021-09-22 | University of Massachusetts | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
| CN107980062B (zh) | 2015-04-03 | 2022-11-25 | 马萨诸塞大学 | 用于靶向亨廷汀mRNA的寡核苷酸化合物 |
| JP6983752B2 (ja) | 2015-07-06 | 2021-12-17 | フィオ ファーマシューティカルズ コーポレーションPhio Pharmaceuticals Corp. | スーパーオキシドディスムターゼ１（ｓｏｄ１）を標的とする核酸分子 |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| CA3002744A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| EP3408391A4 (en) | 2016-01-31 | 2019-08-28 | University of Massachusetts | BRANCHED OLIGONUCLEOTIDES |
| WO2018031933A2 (en) | 2016-08-12 | 2018-02-15 | University Of Massachusetts | Conjugated oligonucleotides |
| JP7406793B2 (ja) | 2017-06-23 | 2023-12-28 | ユニバーシティー オブ マサチューセッツ | ２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法 |
| WO2019143685A1 (en) * | 2018-01-16 | 2019-07-25 | Women & Infants Hospital Of Rhode Island | Methods and compositions for treating pre-eclampsia |
| EP3833763A4 (en) | 2018-08-10 | 2023-07-19 | University of Massachusetts | MODIFIED OLIGONUCLEOTIDES TARGETING SNPs |
| EP3840759A4 (en) | 2018-08-23 | 2022-06-01 | University Of Massachusetts | O-METHYL RICH FULLY STABILIZED OLIGONUCLEOTIDES |
| US20220112503A1 (en) * | 2018-12-21 | 2022-04-14 | Ionis Pharmaceuticals, Inc. | Compounds and methods for reducing pmp22 expression |
| JP2022523467A (ja) | 2019-01-18 | 2022-04-25 | ユニバーシティ・オブ・マサチューセッツ | 動的な薬物動態を修飾するアンカー |
| US20200318113A1 (en) * | 2019-03-05 | 2020-10-08 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
| KR20220047989A (ko) | 2019-08-09 | 2022-04-19 | 유니버시티 오브 매사추세츠 | Snp를 표적화하는 화학적으로 변형된 올리고뉴클레오타이드 |
| AU2021382621A1 (en) * | 2020-11-23 | 2023-06-22 | University Of Massachusetts | Oligonucleotides for dgat2 modulation |
| WO2022271786A1 (en) * | 2021-06-23 | 2022-12-29 | University Of Massachusetts | Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US5240848A (en) | 1988-11-21 | 1993-08-31 | Monsanto Company | Dna sequences encoding human vascular permeability factor having 189 amino acids |
| US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| US5332671A (en) | 1989-05-12 | 1994-07-26 | Genetech, Inc. | Production of vascular endothelial cell growth factor and DNA encoding same |
| US5219739A (en) | 1989-07-27 | 1993-06-15 | Scios Nova Inc. | DNA sequences encoding bVEGF120 and hVEGF121 and methods for the production of bovine and human vascular endothelial cell growth factors, bVEGF120 and hVEGF121 |
| US5194596A (en) | 1989-07-27 | 1993-03-16 | California Biotechnology Inc. | Production of vascular endothelial cell growth factor |
| EP0500799B1 (en) | 1989-11-16 | 1998-01-14 | Duke University | Particle mediated transformation of animal skin tissue cells |
| US6291438B1 (en) | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
| US5858988A (en) | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
| TW404844B (en) | 1993-04-08 | 2000-09-11 | Oxford Biosciences Ltd | Needleless syringe |
| AU5545596A (en) | 1995-04-28 | 1996-11-18 | Medtronic, Inc. | Intraparenchymal infusion catheter system |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US5735814A (en) | 1996-04-30 | 1998-04-07 | Medtronic, Inc. | Techniques of treating neurodegenerative disorders by brain infusion |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| WO2005121370A2 (en) | 2004-06-03 | 2005-12-22 | Isis Pharmaceuticals, Inc. | Oligomeric compounds that facilitate risc loading |
| US6177403B1 (en) | 1996-10-21 | 2001-01-23 | The Trustees Of The University Of Pennsylvania | Compositions, methods, and apparatus for delivery of a macromolecular assembly to an extravascular tissue of an animal |
| US6042820A (en) | 1996-12-20 | 2000-03-28 | Connaught Laboratories Limited | Biodegradable copolymer containing α-hydroxy acid and α-amino acid units |
| US6472375B1 (en) | 1998-04-16 | 2002-10-29 | John Wayne Cancer Institute | DNA vaccine and methods for its use |
| EP1016726A1 (en) | 1998-12-30 | 2000-07-05 | Introgene B.V. | Gene therapy to promote angiogenesis |
| EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
| CA2937159C (en) | 2001-09-28 | 2017-11-28 | Thomas Tuschl | Microrna molecules |
| AU2003223775A1 (en) | 2002-04-30 | 2003-11-17 | Duke University | Adeno-associated viral vectors and methods for their production from hybrid adenovirus and for their use |
| ES2534294T3 (es) | 2002-07-19 | 2015-04-21 | Beth Israel Deaconess Medical Center | Métodos para tratar la preeclampsia |
| CA2504929C (en) | 2002-11-05 | 2014-07-22 | Charles Allerson | Compositions comprising alternating 2'-modified nucleosides for use in gene modulation |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| PT2284266E (pt) | 2002-11-14 | 2013-12-17 | Thermo Fisher Scient Biosciences Inc | Siarn contra tp53 |
| US7217807B2 (en) * | 2002-11-26 | 2007-05-15 | Rosetta Genomics Ltd | Bioinformatically detectable group of novel HIV regulatory genes and uses thereof |
| US20040198640A1 (en) * | 2003-04-02 | 2004-10-07 | Dharmacon, Inc. | Stabilized polynucleotides for use in RNA interference |
| US7750144B2 (en) | 2003-06-02 | 2010-07-06 | University Of Massachusetts | Methods and compositions for enhancing the efficacy and specificity of RNA silencing |
| EP1633890B2 (en) | 2003-06-02 | 2020-11-18 | University of Massachusetts | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF FNAi |
| DK1633767T3 (da) | 2003-06-02 | 2019-03-25 | Univ Massachusetts | Fremgangsmåder og sammensætninger til styring af virkning af rna-silencing |
| CN1906308B (zh) | 2003-12-19 | 2011-09-14 | 诺华疫苗和诊断公司 | 小干扰rna的细胞转染制剂、相关组合物以及制备和使用方法 |
| WO2005077333A2 (en) | 2004-02-10 | 2005-08-25 | University Of Florida Research Foundation, Inc. | Gel-based delivery of recombinant adeno-associated virus vectors |
| ES2423060T3 (es) * | 2004-03-12 | 2013-09-17 | Alnylam Pharmaceuticals, Inc. | Agentes iRNA que tienen como diana al VEGF |
| WO2006019430A2 (en) | 2004-04-20 | 2006-02-23 | Nastech Pharmaceutical Company Inc. | Methods and compositions for enhancing delivery of double-stranded rna or a double-stranded hybrid nucleic acid to regulate gene expression in mammalian cells |
| NZ555830A (en) | 2004-12-15 | 2009-01-31 | Univ North Carolina | Chimeric vectors |
| US20070105803A1 (en) | 2005-08-18 | 2007-05-10 | Muthiah Manoharan | Methods and compositions for treating neurological disease |
| WO2007051045A2 (en) | 2005-10-28 | 2007-05-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of huntingtin gene |
| US8101741B2 (en) * | 2005-11-02 | 2012-01-24 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
| WO2007087451A2 (en) | 2006-01-25 | 2007-08-02 | University Of Massachusetts | Compositions and methods for enhancing discriminatory rna interference |
| US9198981B2 (en) * | 2006-02-01 | 2015-12-01 | The University Of Kentucky | Modulation of angiogenesis |
| US20080039415A1 (en) | 2006-08-11 | 2008-02-14 | Gregory Robert Stewart | Retrograde transport of sirna and therapeutic uses to treat neurologic disorders |
| WO2008154482A2 (en) | 2007-06-08 | 2008-12-18 | Sirnaomics, Inc. | Sirna compositions and methods of use in treatment of ocular diseases |
| CN101199858A (zh) | 2007-10-18 | 2008-06-18 | 广州拓谱基因技术有限公司 | 治疗眼科疾病的多靶点小干扰rna鸡尾酒制剂及制备方法 |
| WO2009099991A2 (en) | 2008-01-31 | 2009-08-13 | The Brigham And Women's Hospital, Inc. | Treatment of cancer |
| US9217155B2 (en) | 2008-05-28 | 2015-12-22 | University Of Massachusetts | Isolation of novel AAV'S and uses thereof |
| CA2743981C (en) | 2008-09-22 | 2019-01-29 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering rnai compounds |
| WO2010090762A1 (en) | 2009-02-04 | 2010-08-12 | Rxi Pharmaceuticals Corporation | Rna duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| EP3272870A1 (en) | 2009-08-27 | 2018-01-24 | Idera Pharmaceuticals, Inc. | Compositions for inhibiting gene expression and uses thereof |
| EP2550000A4 (en) | 2010-03-24 | 2014-03-26 | Advirna Inc | RNAI COMPOUNDS OF REDUCED SIZE ADMINISTERING |
| CN103154014B (zh) | 2010-04-28 | 2015-03-25 | Isis制药公司 | 修饰核苷、其类似物以及由它们制备的寡聚化合物 |
| WO2012005898A2 (en) | 2010-06-15 | 2012-01-12 | Alnylam Pharmaceuticals, Inc. | Chinese hamster ovary (cho) cell transcriptome, corresponding sirnas and uses thereof |
| CN103562387A (zh) | 2011-03-03 | 2014-02-05 | 夸克医药公司 | Toll样受体途径的寡核苷酸调剂 |
| EP3919620A1 (en) | 2012-05-02 | 2021-12-08 | Sirna Therapeutics, Inc. | Short interfering nucleic acid (sina) compositions |
| KR20150083920A (ko) | 2012-11-15 | 2015-07-20 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | 항 apob 안티센스 접합체 화합물 |
| EP3733856A1 (en) | 2014-04-18 | 2020-11-04 | University of Massachusetts | Exosomal loading using hydrophobically modified oligonucleotides |
| WO2016161388A1 (en) | 2015-04-03 | 2016-10-06 | University Of Massachusetts | Fully stabilized asymmetric sirna |
| CN107980062B (zh) | 2015-04-03 | 2022-11-25 | 马萨诸塞大学 | 用于靶向亨廷汀mRNA的寡核苷酸化合物 |
| EP3277815B1 (en) | 2015-04-03 | 2021-09-22 | University of Massachusetts | Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders |
| WO2017030973A1 (en) | 2015-08-14 | 2017-02-23 | University Of Massachusetts | Bioactive conjugates for oligonucleotide delivery |
| EP3408391A4 (en) | 2016-01-31 | 2019-08-28 | University of Massachusetts | BRANCHED OLIGONUCLEOTIDES |
-
2016
- 2016-04-01 EP EP16716413.6A patent/EP3277815B1/en active Active
- 2016-04-01 CA CA2980339A patent/CA2980339A1/en active Pending
- 2016-04-01 US US15/089,437 patent/US9862952B2/en active Active
- 2016-04-01 ES ES16716413T patent/ES2901455T3/es active Active
- 2016-04-01 PT PT167164136T patent/PT3277815T/pt unknown
- 2016-04-01 RS RS20211483A patent/RS62672B1/sr unknown
- 2016-04-01 DK DK16716413.6T patent/DK3277815T3/da active
- 2016-04-01 HU HUE16716413A patent/HUE057431T2/hu unknown
- 2016-04-01 EP EP21197881.2A patent/EP3995581A3/en active Pending
- 2016-04-01 SI SI201631368T patent/SI3277815T1/sl unknown
- 2016-04-01 PL PL16716413T patent/PL3277815T3/pl unknown
- 2016-04-01 WO PCT/US2016/025731 patent/WO2016161378A1/en unknown
-
2017
- 2017-11-15 US US15/814,350 patent/US10519451B2/en active Active
-
2019
- 2019-11-06 US US16/675,369 patent/US11345917B2/en active Active
-
2022
- 2022-04-12 US US17/718,918 patent/US20220364100A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US9862952B2 (en) | 2018-01-09 |
| SI3277815T1 (sl) | 2022-01-31 |
| US20200165618A1 (en) | 2020-05-28 |
| EP3995581A2 (en) | 2022-05-11 |
| PL3277815T3 (pl) | 2022-03-21 |
| US20160355826A1 (en) | 2016-12-08 |
| ES2901455T3 (es) | 2022-03-22 |
| PT3277815T (pt) | 2021-11-11 |
| HUE057431T2 (hu) | 2022-05-28 |
| WO2016161378A1 (en) | 2016-10-06 |
| EP3995581A3 (en) | 2022-10-26 |
| CA2980339A1 (en) | 2016-10-06 |
| US11345917B2 (en) | 2022-05-31 |
| US20180179546A1 (en) | 2018-06-28 |
| RS62672B1 (sr) | 2021-12-31 |
| EP3277815B1 (en) | 2021-09-22 |
| US20220364100A1 (en) | 2022-11-17 |
| US10519451B2 (en) | 2019-12-31 |
| EP3277815A1 (en) | 2018-02-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3277815T3 (da) | Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser | |
| DK3570844T3 (da) | Azolopyrimidin til behandlingen af kræftrelaterede lidelser | |
| DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
| DK3212233T3 (da) | Kombinationsterapi til behandling af sygdom | |
| DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
| DK3882250T3 (da) | Tetrahydropyranyl-amino-pyrrolopyrimidinon til anvendelse i behandling af btk-medierede forstyrrelser | |
| DK3224269T3 (da) | Sammensætninger og fremgangsmåder til behandling af cns-forstyrrelser | |
| DK3212226T3 (da) | Sammensætninger og anvendelsesfremgangsmåder til behandling af metaboliske lidelser | |
| DK3481846T3 (da) | 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande | |
| DK3240612T3 (da) | Fremgangsmåder til behandling af nethindesygdomme | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
| DK3157534T3 (da) | Acetylcholinesterasehæmmere til behandling af dermatologiske tilstande | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
| DK3302519T3 (da) | Ornithodoros-moubata-komplement-inhibitor til anvendelse i behandlingen af akut graft-versus-host-sygdom | |
| IL256103B (en) | Compositions and methods for treating celiac sprue disease | |
| DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
| DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
| DK3256466T3 (da) | 1-heterocyclyl-isochromanylforbindelser og analoger til behandling af cns-forstyrrelser | |
| DK3157522T3 (da) | Muskarin-antagonister og kombinationer deraf til behandlingen af luftvejssygdomme i heste | |
| EP3733613A4 (en) | Wastewater treatment method | |
| DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
| DK3236960T3 (da) | Fluralaner til anvendelse i behandling af demodicose | |
| DK3331610T3 (da) | Midler til anvendelse til behandling af gliom |